<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600778</url>
  </required_header>
  <id_info>
    <org_study_id>LVC-N91115-PS-II-01</org_study_id>
    <nct_id>NCT04600778</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GSNOR Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GSNOR Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief Summary: The purpose of this study is to to evaluate the efficacy and safety of&#xD;
      Cavosonstat administered twice daily compared with Placebo for 24 Weeks in adult subjects&#xD;
      with Chronic Obstructive Pulmonary Disease (COPD)&#xD;
&#xD;
      Detailed Description:To investigate the effect of cavosonstat compared with placebo, on the&#xD;
      annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over 24 weeks of&#xD;
      treatment.&#xD;
&#xD;
      To investigate:&#xD;
&#xD;
        1. The effect of cavosonstat compared with placebo, on the duration from baseline to first&#xD;
           moderate AECOPD event&#xD;
&#xD;
        2. The effect of cavosonstat compared with placebo, on respiratory function, as assessed by&#xD;
           post-bronchodilator percent-predicted forced expiratory volume in one second (ppFEV1)&#xD;
&#xD;
        3. The effect of cavosonstat compared with placebo on annualized rate of moderate AECOPD&#xD;
           over 24 weeks of treatment&#xD;
&#xD;
        4. The effect of cavosonstat compared with placebo on annualized rate of severe AECOPD over&#xD;
           24 weeks of treatment&#xD;
&#xD;
        5. The safety and tolerability of cavosonstat compared with placebo&#xD;
&#xD;
        6. The pharmacokinetics of cavosonstat&#xD;
&#xD;
        7. Assessment of quality of life&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 3, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized rate of moderate-to-severe acute exacerbations of COPD</measure>
    <time_frame>24 weeks</time_frame>
    <description>To investigate the effect of cavosonstat compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over 24 weeks of treatment.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavosonstat 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavosonstat 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavosonstat 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavosonstat 5 mg</intervention_name>
    <description>Cavosonstat (low dose)</description>
    <arm_group_label>Cavosonstat 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavosonstat 10 mg</intervention_name>
    <description>Cavosonstat (medium dose)</description>
    <arm_group_label>Cavosonstat 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavosonstat 25 mg</intervention_name>
    <description>Cavosonstat (high dose)</description>
    <arm_group_label>Cavosonstat 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with moderate to severe COPD, who meet the following criteria (full details&#xD;
             in main text):&#xD;
&#xD;
               -  Male or female aged between 40 and 75 years inclusive, at the time of informed&#xD;
                  consent&#xD;
&#xD;
               -  Patients with symptomatic COPD as defined by the 2019 GOLD diagnostic criteria&#xD;
&#xD;
               -  Post-bronchodilator (four puffs of albuterol) spirometry at screening&#xD;
                  demonstrating the following:&#xD;
&#xD;
                    1. FEV1/forced vital capacity (FVC) ratio of &lt;0.70&#xD;
&#xD;
                    2. FEV1 ≥30% and FEV1 &lt;80% of predicted normal&#xD;
&#xD;
               -  Current or prior history of ≥10 pack-years of cigarette smoking&#xD;
&#xD;
               -  Participants with COPD Assessment Test (CAT) score ≥10 at screening&#xD;
&#xD;
               -  Participants with a documented history of ≥1 moderate exacerbation within the&#xD;
                  year prior to screening&#xD;
&#xD;
               -  Participants with standard of care background therapy for three months and at a&#xD;
                  stable dose for at least one month, including either:&#xD;
&#xD;
               -  Single therapy: long-acting muscarinic agonist (LAMA), or&#xD;
&#xD;
               -  Double therapy: long-acting beta agonist (LABA) plus long-acting muscarinic&#xD;
                  agonist (LAMA) or inhaled corticosteroid (ICS) plus LABA or ICS plus LAMA, or&#xD;
&#xD;
               -  Triple therapy: LABA plus LAMA plus ICS&#xD;
&#xD;
               -  Meet the concomitant medication restrictions and continue to do so throughout the&#xD;
                  study&#xD;
&#xD;
               -  Have body mass index &gt;21 kg/m2 and &lt; 35 kg/m2&#xD;
&#xD;
               -  Males must agree not to donate sperm. They must be sexually abstinent or use a&#xD;
                  condom with all sexual partners. If the partner is of child-bearing potential, a&#xD;
                  condom with spermicide and a second reliable form of contraception must also be&#xD;
                  used&#xD;
&#xD;
               -  Females must be of non-childbearing potential, be sexually abstinent or use a&#xD;
                  highly effective form of contraception.&#xD;
&#xD;
               -  Able to sign an informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients meeting any of the following criteria must be excluded from the study (full&#xD;
             details in main text):&#xD;
&#xD;
               -  Patients with other respiratory disorders: current diagnosis of asthma, active&#xD;
                  tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis,&#xD;
                  interstitial lung diseases, uncontrolled or unstable sleep apnea, cor pulmonale,&#xD;
                  clinically significant pulmonary hypertension or other active pulmonary diseases&#xD;
&#xD;
               -  Chest X-ray (or computerized tomography [CT] scan) reveals evidence of clinically&#xD;
                  significant abnormalities not believed to be due to the presence of COPD&#xD;
&#xD;
               -  Moderate or severe AECOPD within the previous four weeks&#xD;
&#xD;
               -  An upper or lower respiratory tract infection that required the use of&#xD;
                  antibiotics within the previous four weeks&#xD;
&#xD;
               -  Long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for more&#xD;
                  than 12 hours a day&#xD;
&#xD;
               -  Oral therapies for COPD (e.g. oral steroids, theophylline and roflumilast) or&#xD;
                  antibiotics or oral corticosteroid therapy within four weeks prior to screening&#xD;
&#xD;
               -  Prior history of, or planned pneumonectomy or lung volume reduction surgery&#xD;
&#xD;
               -  Participation in the acute phase of a pulmonary rehabilitation program within&#xD;
                  four weeks of screening or planned during the study&#xD;
&#xD;
               -  History of malignancy of any organ system within five years, except skin cancer&#xD;
                  which has been stable over one year and the investigator believes is no clinical&#xD;
                  significance.&#xD;
&#xD;
               -  Patients with uncontrolled disease including, but not limited to, endocrine,&#xD;
                  active hyperthyroidism, neurological, hepatic, gastrointestinal, renal,&#xD;
                  hematological, urological, immunological, psychiatric, or ophthalmic diseases&#xD;
                  that the Investigator believes are clinically significant. This includes any&#xD;
                  hepatic disease or moderate to severe renal impairment.&#xD;
&#xD;
               -  Documented clinically significant cardiovascular disease such as: any history of&#xD;
                  arrhythmias, angina, recent (&lt;1 year) or suspected myocardial infarction,&#xD;
                  congestive heart failure, unstable or uncontrolled hypertension, or diagnosis of&#xD;
                  hypertension within 3 months prior to Screening.&#xD;
&#xD;
               -  Known or suspected history of alcohol or drug abuse within the last 5 years.&#xD;
                  Positive urine drug screen and blood alcohol level screen.&#xD;
&#xD;
               -  Clinically significant abnormal values for laboratory safety tests (hematology,&#xD;
                  blood chemistry, viral serology or urinalysis) at Screening, as determined by the&#xD;
                  Investigator.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than&#xD;
                  twice the upper limit of normal.&#xD;
&#xD;
               -  Received an experimental drug within 30 days or five half-lives, whichever is&#xD;
                  longer.&#xD;
&#xD;
               -  Women who are pregnant or breast-feeding.&#xD;
&#xD;
               -  Prior exposure to a GSNOR inhibitor.&#xD;
&#xD;
               -  Major surgery (requiring general anesthesia) within 6 weeks prior to Screening,&#xD;
                  lack of full recovery from surgery at Screening, or planned surgery through the&#xD;
                  end of the study.&#xD;
&#xD;
               -  A disclosed history or one known to the Investigator, of significant&#xD;
                  non-compliance in previous investigational studies or with prescribed&#xD;
                  medications.&#xD;
&#xD;
               -  Any other reason that the Investigator considers makes the patient unsuitable to&#xD;
                  participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

